US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US4920016A
(en)
|
1986-12-24 |
1990-04-24 |
Linear Technology, Inc. |
Liposomes with enhanced circulation time
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
DE68927933T2
(de)
|
1988-09-02 |
1997-08-14 |
Dyax Corp |
Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
JPH06508511A
(ja)
|
1990-07-10 |
1994-09-29 |
ケンブリッジ アンティボディー テクノロジー リミティド |
特異的な結合ペアーの構成員の製造方法
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
EP0814159B1
(en)
|
1990-08-29 |
2005-07-27 |
GenPharm International, Inc. |
Transgenic mice capable of producing heterologous antibodies
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
EP0575485A1
(en)
|
1991-03-01 |
1993-12-29 |
Dyax Corp. |
Process for the development of binding mini-proteins
|
JP3672306B2
(ja)
|
1991-04-10 |
2005-07-20 |
ザ スクリップス リサーチ インスティテュート |
ファージミドを使用するヘテロ二量体受容体ライブラリー
|
US5871907A
(en)
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US6214334B1
(en)
|
1991-10-21 |
2001-04-10 |
Trustees Of The University Of Pennsylvania |
Compositions and methods for producing and using homogenous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries
|
US5681747A
(en)
|
1992-03-16 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
AU687010B2
(en)
|
1992-07-17 |
1998-02-19 |
Dana-Farber Cancer Institute |
Method of intracellular binding of target molecules
|
DE4239877C1
(de)
|
1992-11-27 |
1994-03-17 |
Boehringer Ingelheim Int |
Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
|
WO1995003832A1
(en)
|
1993-07-30 |
1995-02-09 |
Thomas Jefferson University |
Intracellular immunization
|
FR2721943B1
(fr)
|
1994-06-29 |
1996-08-02 |
Rhone Poulenc Rorer Sa |
Adenovirus comprenant un gene codant pour une superoxyde dismutase
|
US5556837A
(en)
|
1994-08-01 |
1996-09-17 |
Regeneron Pharmaceuticals Inc. |
Methods for treating addictive disorders
|
US5614649A
(en)
|
1994-11-14 |
1997-03-25 |
Cephalon, Inc. |
Multicatalytic protease inhibitors
|
US5783683A
(en)
|
1995-01-10 |
1998-07-21 |
Genta Inc. |
Antisense oligonucleotides which reduce expression of the FGFRI gene
|
US5853987A
(en)
|
1995-04-24 |
1998-12-29 |
The Texas A & M University System |
Decorin binding protein compositions and methods of use
|
US5834457A
(en)
|
1996-01-26 |
1998-11-10 |
The Regents Of The University Of California |
Method of modulating radical formation by mutant cuznsod enzymes
|
AU6564798A
(en)
|
1997-03-18 |
1998-10-12 |
Brigham And Women's Hospital |
Methods and kits for treating and diagnosing leiomyomas
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
US6723694B1
(en)
|
1997-05-21 |
2004-04-20 |
The Children's Medical Center Corp. |
Short peptides which selectively modulate intracellular signalling
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
US6096778A
(en)
|
1997-10-07 |
2000-08-01 |
Cephalon, Inc. |
α-ketoamide multicatalytic protease inhibitors
|
US20010006793A1
(en)
|
1998-03-20 |
2001-07-05 |
Mary-Ann Bjornsti |
Modulators of eukaryotic caspases
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
CA2334528A1
(en)
|
1998-06-15 |
1999-12-23 |
Peter David Gluckman |
Regulation of tyrosine hydroxylase
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
US6319905B1
(en)
|
1998-12-29 |
2001-11-20 |
Cell Genesys, Inc. |
Method of controlling L-Dopa production and of treating dopamine deficiency
|
US6841567B1
(en)
|
1999-02-12 |
2005-01-11 |
Cephalon, Inc. |
Cyclic substituted fused pyrrolocarbazoles and isoindolones
|
US6624171B1
(en)
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
US6312949B1
(en)
|
1999-03-26 |
2001-11-06 |
The Salk Institute For Biological Studies |
Regulation of tyrosine hydroxylase expression
|
US6297238B1
(en)
|
1999-04-06 |
2001-10-02 |
Basf Aktiengesellschaft |
Therapeutic agents
|
US6982265B1
(en)
|
1999-05-21 |
2006-01-03 |
Bristol Myers Squibb Company |
Pyrrolotriazine inhibitors of kinases
|
US20030125276A1
(en)
|
2001-11-08 |
2003-07-03 |
Isis Pharmaceuticals Inc. |
Antisense modulation of thyroid hormone receptor interactor 6 expression
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
US6797720B2
(en)
|
1999-12-03 |
2004-09-28 |
Ono Pharmaceutical Co., Ltd. |
1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient
|
AU1650401A
(en)
|
1999-12-03 |
2001-06-25 |
Ono Pharmaceutical Co. Ltd. |
Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
|
US6334998B1
(en)
|
1999-12-07 |
2002-01-01 |
Parker Hughes Institute |
Estrogens for treating ALS
|
JP2003518123A
(ja)
|
1999-12-21 |
2003-06-03 |
スージェン・インコーポレーテッド |
4−置換7−アザ−インドリン−2−オンおよびその蛋白質キナーゼ阻害剤としての使用
|
US7108984B2
(en)
|
2000-01-12 |
2006-09-19 |
Mount Sinai School Of Medicine |
Methods of identifying modulators of the FGF receptor
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
AU2001228810A1
(en)
|
2000-01-26 |
2001-08-07 |
Ono Pharmaceutical Co. Ltd. |
Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
|
JP2001292778A
(ja)
|
2000-04-11 |
2001-10-23 |
Inst Of Physical & Chemical Res |
トランケート型リーリンタンパク質およびそれをコードするdna
|
US6372250B1
(en)
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
US20030211967A1
(en)
|
2001-05-07 |
2003-11-13 |
Bryant Henry Uhlman |
Method for selectively inhibiting ghrelin action
|
US6967237B2
(en)
|
2000-05-30 |
2005-11-22 |
Merck & Co., Inc. |
Ghrelin analogs
|
AU2001269095A1
(en)
|
2000-06-26 |
2002-01-08 |
Bayer Aktiengesellschaft |
Regulation of human caspase-1-like protease
|
JP2002017361A
(ja)
|
2000-07-04 |
2002-01-22 |
Inst Of Physical & Chemical Res |
リーリンタンパク質cr−50エピトープ領域
|
JP4409135B2
(ja)
*
|
2000-12-01 |
2010-02-03 |
武田薬品工業株式会社 |
生理活性物質含有製剤の製造法
|
US7381701B2
(en)
|
2001-02-15 |
2008-06-03 |
The Borad Of Trustees Of The University Of Illinois |
Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
|
JPWO2002077226A1
(ja)
|
2001-03-23 |
2004-07-15 |
小野薬品工業株式会社 |
プロスタグランジンep1受容体
|
US20030077298A1
(en)
|
2001-04-13 |
2003-04-24 |
The Regents Of The University Of California, A California Corporation |
Activators and ligands of PPAR-beta/delta for the treatment of skin conditions
|
US20070021360A1
(en)
|
2001-04-24 |
2007-01-25 |
Nyce Jonathan W |
Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
|
US20050182006A1
(en)
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
US20040204368A1
(en)
|
2001-05-31 |
2004-10-14 |
Kazuyuki Ohmoto |
Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
|
US7736677B2
(en)
|
2001-06-20 |
2010-06-15 |
Metaproteomics, Llc |
Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
WO2003004057A1
(en)
|
2001-07-03 |
2003-01-16 |
The Hospital For Sick Children |
Ephrin and eph receptor mediated immune modulation
|
DE10134196B4
(de)
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
US7348140B1
(en)
|
2001-07-25 |
2008-03-25 |
Acadia Pharmaceuticals, Inc. |
Clinical indications for genotyping polymorphic variants of G-protein coupled receptors
|
ATE420654T1
(de)
|
2001-08-15 |
2009-01-15 |
Univ Brown Res Found |
Behandlung von muskeldystrophien und verwandter erkrankungen
|
AU2002322911A1
(en)
|
2001-08-16 |
2003-03-03 |
Angiogene Inc. |
Use of alphacp1, alphacp2, and hur for modulating gene expression and inducing angiogenesis
|
KR20040053122A
(ko)
|
2001-09-07 |
2004-06-23 |
더 트러스티즈 오브 보스톤 유니버시티 |
면역 복합체 관련 질환의 치료 방법 및 이를 위한 조성물
|
WO2003031573A2
(en)
|
2001-10-05 |
2003-04-17 |
Coley Pharmaceutical Gmbh |
Toll-like receptor 3 signaling agonists and antagonists
|
US20030078199A1
(en)
|
2001-10-09 |
2003-04-24 |
Youmin Shu |
Human EphA6 gene and polypeptide
|
DE60232739D1
(de)
|
2001-10-12 |
2009-08-06 |
Nippon Chemiphar Co |
Aktivator des peroxisomproliferator-aktivierten rezeptors delta
|
EP1442062A4
(en)
|
2001-10-18 |
2005-11-09 |
Genentech Inc |
METHOD FOR TREATING CARCINOMA
|
EP1469730A4
(en)
|
2001-10-30 |
2006-02-01 |
|
METHOD AND COMPOSITIONS FOR TREATING PARKINSON DISEASE
|
US7141572B2
(en)
|
2001-11-05 |
2006-11-28 |
Merck Patent Gesellschaft |
Hydrazono-malonitriles
|
US20030165485A1
(en)
|
2001-11-09 |
2003-09-04 |
Goran Bertilsson |
Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
|
AU2002365887A1
(en)
|
2001-11-29 |
2003-06-17 |
U.S. Department Of Veterans Affairs |
Use of gingko biloba extracts to promote neuroprotection and reduce weight loss
|
CN100522946C
(zh)
|
2001-12-06 |
2009-08-05 |
法布罗根股份有限公司 |
低氧诱导因子(HIF)α的稳定化
|
WO2003051387A1
(fr)
|
2001-12-19 |
2003-06-26 |
Itoham Foods Inc. |
Agents therapeutiques et/ou prophylactiques contre des maladies conformationnelles
|
DK1469878T3
(da)
|
2002-01-31 |
2011-07-18 |
Max Planck Gesellschaft |
FGFR agonister
|
US20030225098A1
(en)
|
2002-03-21 |
2003-12-04 |
Hirst Gavin C. |
Kinase inhibitors
|
US20030199525A1
(en)
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
KR20050004809A
(ko)
|
2002-03-22 |
2005-01-12 |
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. |
말초 맥관 질환 치료 및/또는 예방에 사용되는 il-18저해제
|
EP1490696A2
(en)
|
2002-03-26 |
2004-12-29 |
Bayer Aktiengesellschaft |
Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
IL162796A0
(en)
|
2002-05-21 |
2005-11-20 |
Kenji Kangawa |
Medicinal compositions containing ghrelin
|
WO2003103599A2
(en)
|
2002-06-05 |
2003-12-18 |
Sunesis Pharmaceuticals, Inc. |
Caspase-1 inhibitors and methods for their use
|
US20040022765A1
(en)
|
2002-07-31 |
2004-02-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Ran GTPase activating protein 1 expression
|
ATE481133T1
(de)
|
2002-07-05 |
2010-10-15 |
Chugai Pharmaceutical Co Ltd |
Mittel zum senken des blutglukosespiegels
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
EP1530635B1
(en)
*
|
2002-08-01 |
2011-06-15 |
Noxxon Pharma AG |
Ghrelin binding nucleic acids
|
WO2004013145A1
(en)
|
2002-08-02 |
2004-02-12 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
DE10244453A1
(de)
|
2002-09-24 |
2004-04-01 |
Phenomiques Gmbh |
Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
|
EP1407760A1
(de)
|
2002-10-08 |
2004-04-14 |
Cognis France S.A. |
Verfahren zum Schutz der Haut gegen Alterung
|
CN101899106A
(zh)
|
2002-10-29 |
2010-12-01 |
阿纳福公司 |
三聚细胞因子的三聚结合蛋白
|
AU2003290586B2
(en)
|
2002-11-04 |
2009-07-02 |
University Of Massachusetts |
Allele-specific RNA interference
|
DK2284266T3
(da)
|
2002-11-14 |
2014-01-13 |
Thermo Fisher Scient Biosciences Inc |
sIRNA-MOLEKYLE MOD TP53
|
JP3810731B2
(ja)
|
2002-11-29 |
2006-08-16 |
独立行政法人科学技術振興機構 |
哺乳動物のToll様受容体3に結合する新規アダプタータンパク質およびその遺伝子
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
AU2003287930A1
(en)
|
2002-12-20 |
2004-07-14 |
Neuronicon Aps |
Modulation of activity of neurotrophins
|
CA2513584A1
(en)
|
2003-01-20 |
2004-08-05 |
Vib Vzw |
The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
|
US7354933B2
(en)
|
2003-01-31 |
2008-04-08 |
Aventis Pharma Sa |
Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
US8227212B2
(en)
|
2003-02-11 |
2012-07-24 |
Shire Human Genetic Therapies, Inc. |
Cell that expresses a sulfatase and a formylglycine generating enzyme
|
US20040220270A1
(en)
|
2003-03-07 |
2004-11-04 |
The Jackson Laboratory |
Methods and composition of treating glaucoma by modulating tyrosinase/L-DOPA pathway
|
WO2004087066A2
(en)
|
2003-03-27 |
2004-10-14 |
Emory University |
Hif-1 inhibitors
|
WO2004093812A2
(en)
|
2003-04-22 |
2004-11-04 |
Irm Llc |
Compounds that induce neuronal differentiation in embryonic stem cells
|
US20040242559A1
(en)
|
2003-04-25 |
2004-12-02 |
Aventis Pharma S.A. |
Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
ATE550029T1
(de)
|
2003-04-30 |
2012-04-15 |
Kenji Kangawa |
Mittel zur prävention oder heilung von hepatopathie
|
US7423031B2
(en)
|
2003-05-01 |
2008-09-09 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
EP1636228B1
(de)
|
2003-05-23 |
2008-10-22 |
AEterna Zentaris GmbH |
Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
US20050002897A1
(en)
|
2003-06-18 |
2005-01-06 |
Ulrich Haupts |
Biological entities and the pharmaceutical or diagnostic use thereof
|
MXPA05013922A
(es)
|
2003-06-20 |
2006-02-24 |
Coley Pharm Group Inc |
Antagonistas de receptor tipo toll de molecula pequena.
|
US8592391B2
(en)
|
2003-07-01 |
2013-11-26 |
Andres Salazar |
Method for therapeutic, clinical and veterinary use poly-ICLC
|
WO2005007111A2
(en)
|
2003-07-11 |
2005-01-27 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
MXPA06001501A
(es)
|
2003-08-07 |
2006-09-04 |
Enkam Pharmaceuticals As |
Compuestos que comprenden lpa.
|
ATE506077T1
(de)
|
2003-10-16 |
2011-05-15 |
Imclone Llc |
Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
|
WO2005040792A2
(en)
|
2003-10-21 |
2005-05-06 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with arginyl aminopeptidase (aminopeptidase b)-like 1 (rnpepl1)
|
GB0325031D0
(en)
|
2003-10-27 |
2003-12-03 |
Novartis Ag |
Organic compounds
|
JP2007510662A
(ja)
|
2003-11-04 |
2007-04-26 |
エリクシアー ファーマシューティカルズ, インコーポレイテッド |
治療化合物およびその使用
|
US7906520B2
(en)
|
2003-11-13 |
2011-03-15 |
The General Hospital Corporation |
Methods for treating pain
|
WO2005048916A2
(en)
|
2003-11-20 |
2005-06-02 |
Biovitrum Ab |
Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
|
JPWO2005051425A1
(ja)
|
2003-11-26 |
2008-04-24 |
第一製薬株式会社 |
プロカスパーゼ1活性化阻害剤
|
US20050171182A1
(en)
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
WO2005066211A2
(en)
|
2003-12-19 |
2005-07-21 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
PT1697370E
(pt)
|
2003-12-19 |
2007-05-31 |
Bristol Myers Squibb Co |
Heterociclos azabicíclicos como moduladores do receptor de canabinóides
|
ES2384940T3
(es)
|
2004-01-16 |
2012-07-16 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Inmunoquinasas
|
US20050222171A1
(en)
|
2004-01-22 |
2005-10-06 |
Guido Bold |
Organic compounds
|
WO2005074923A1
(en)
|
2004-02-03 |
2005-08-18 |
Agt Biosciences Limited |
Methods and compositions
|
US20070134273A1
(en)
|
2004-02-10 |
2007-06-14 |
Francois Romagne |
Composition and method for the treatment of carcinoma
|
EP1742961A4
(en)
|
2004-02-13 |
2009-07-15 |
Boston Biomedical Res Inst |
LOCKING OF FGF SIGNALING
|
EP1737956A2
(en)
|
2004-03-01 |
2007-01-03 |
Massachusetts Institute of Technology |
Rnai-based therapeutics for allergic rhinitis and asthma
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
WO2005090966A2
(en)
|
2004-03-24 |
2005-09-29 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with peroxisome proliferator activated receptor delta (ppard)
|
FR2868422B1
(fr)
|
2004-03-31 |
2006-07-14 |
Aventis Pharma Sa |
Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
JP4813461B2
(ja)
|
2004-04-01 |
2011-11-09 |
アベンティス・ファーマスーティカルズ・インコーポレイテツド |
Pparデルタモジュレーターとしての1,3,4−オキサジアゾール−2−オン、および、それらの使用
|
EP1737440A2
(en)
|
2004-04-01 |
2007-01-03 |
Aventis Pharmaceuticals, Inc. |
Use of ppar delta agonists for treating demyelinating diseases
|
US7498316B2
(en)
|
2004-04-06 |
2009-03-03 |
University Of Massachusetts |
Methods and compositions for treating gain-of-function disorders using RNA interference
|
WO2005099741A1
(ja)
|
2004-04-08 |
2005-10-27 |
Noevir Co., Ltd. |
運動ニューロン疾患治療薬
|
US7838645B2
(en)
*
|
2004-04-30 |
2010-11-23 |
University Of Maryland College Park |
Function of autophagy genes in cell death
|
US7357933B2
(en)
|
2004-05-05 |
2008-04-15 |
Enhan Technology Holdings International Co., Ltd. |
Sporoderm-broken germination-activated ganoderma lucidum spores for protection of dopaminergic neurons and treatment of Parkinson's disease
|
AU2005245896A1
(en)
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
AU2005247409B2
(en)
|
2004-05-15 |
2011-11-10 |
Vertex Pharmaceuticals Incorporated |
Treating seizures using ICE inhibitors
|
GB0411791D0
(en)
|
2004-05-26 |
2004-06-30 |
Cyclacel Ltd |
Compounds
|
JP2008501628A
(ja)
|
2004-06-02 |
2008-01-24 |
武田薬品工業株式会社 |
インドール誘導体およびがんの治療用途
|
WO2005120570A2
(en)
|
2004-06-03 |
2005-12-22 |
The University Of Maryland, Baltimore |
Therapeutic targeting of parc/ccl18 and its signaling in pulmonary fibrosis
|
MXPA06014126A
(es)
|
2004-06-04 |
2007-07-18 |
Regeneron Pharma |
Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
|
US7102002B2
(en)
|
2004-06-16 |
2006-09-05 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
CN101027320A
(zh)
|
2004-06-18 |
2007-08-29 |
恩卡姆医药公司 |
Fgfr结合肽
|
CN101018567B
(zh)
|
2004-07-20 |
2011-07-27 |
先灵公司 |
表达Toll样受体的肿瘤细胞凋亡的诱导
|
EP1621539A1
(en)
|
2004-07-27 |
2006-02-01 |
Aventis Pharma S.A. |
Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
EP1621536A1
(en)
|
2004-07-27 |
2006-02-01 |
Aventis Pharma S.A. |
Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
EP1621535A1
(en)
|
2004-07-27 |
2006-02-01 |
Aventis Pharma S.A. |
Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
CA2577060A1
(en)
|
2004-08-13 |
2006-02-23 |
Amgen Inc. |
Substituted benzofused heterocycles
|
US7659374B2
(en)
|
2004-08-16 |
2010-02-09 |
Medimmune, Llc |
Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
|
US20070280886A1
(en)
|
2004-09-09 |
2007-12-06 |
Bayer Healthcare Ag |
Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
|
WO2006030439A2
(en)
|
2004-09-17 |
2006-03-23 |
Biomas Ltd. |
Compositions and methods for inducing hair growth
|
FR2876103B1
(fr)
|
2004-10-01 |
2008-02-22 |
Aventis Pharma Sa |
Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
EP2422811A2
(en)
|
2004-10-27 |
2012-02-29 |
MedImmune, LLC |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
AU2005327921A1
(en)
|
2004-11-01 |
2006-08-31 |
University Of Southern California |
Novel compounds for treatment of cancer and disorders associated with angiogenesis function
|
WO2006054129A1
(en)
|
2004-11-19 |
2006-05-26 |
Institut Gustave Roussy |
Improved treatment of cancer by double-stranded rna
|
EP1662259A1
(en)
|
2004-11-25 |
2006-05-31 |
Cellzome Ag |
Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
|
US20080300180A1
(en)
|
2004-11-30 |
2008-12-04 |
Gastrotech Pharma A/S |
Growth Hormone Secretagogue Receptor 1A Ligands
|
AR051836A1
(es)
|
2004-11-30 |
2007-02-14 |
Centocor Inc |
Antagonistas de receptor 3 simil toll metodos y usos
|
EP1827473A4
(en)
|
2004-12-01 |
2009-08-19 |
Whitehead Biomedical Inst |
MODULATOR OF ALPHA SYNNUCLEINE TOXICITY
|
WO2006066048A2
(en)
|
2004-12-17 |
2006-06-22 |
Beth Israel Deaconess Medical Center |
Compositions for bacterial mediated gene silencing and methods of using same
|
US7834064B2
(en)
|
2005-01-03 |
2010-11-16 |
Andres Mario Salazar |
Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
|
AU2006203850A1
(en)
|
2005-01-10 |
2006-07-13 |
Research Development Foundation |
Targeted chimeric molecules for cancer therapy
|
WO2006076673A2
(en)
|
2005-01-14 |
2006-07-20 |
Regeneron Pharmaceuticals, Inc. |
Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
|
US20060194821A1
(en)
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
CA2598831A1
(en)
|
2005-02-22 |
2006-08-31 |
The Regents Of The University Of California |
Methods of treating gastrointestinal inflammation
|
US20060265767A1
(en)
|
2005-03-02 |
2006-11-23 |
Bruce Beutler |
Compositions and methods for treatment of autoimmune and related diseases
|
EP1877424A4
(en)
|
2005-04-11 |
2010-09-29 |
Pharmagap Inc |
INHIBITORS OF PROTEIN KINASES AND USES THEREOF
|
WO2006122931A1
(en)
|
2005-05-20 |
2006-11-23 |
Biovitrum Ab (Publ) |
Beta-carboline derivatives and theri use as ghsr modulators
|
EP1885181A2
(en)
|
2005-05-23 |
2008-02-13 |
Smithkline Beecham Corporation |
Inhibition of p38 mark for treatment of obesity
|
US7897583B2
(en)
|
2005-05-24 |
2011-03-01 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to PTPRU
|
MX2008000596A
(es)
|
2005-07-11 |
2008-03-19 |
Cbio Ltd |
Inmunomodulacion inducida por la chaperonina 10.
|
GB0515026D0
(en)
|
2005-07-21 |
2005-08-31 |
Novartis Ag |
Organic compounds
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2620351C
(en)
|
2005-08-31 |
2015-04-21 |
Universite Laval |
Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities
|
EP1940436B1
(en)
|
2005-09-06 |
2013-12-04 |
Trinity Therapeutics, Inc. |
Methods for treating immune mediated neurological diseases
|
FR2891273B1
(fr)
|
2005-09-27 |
2007-11-23 |
Aventis Pharma Sa |
NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
|
US7754685B2
(en)
|
2005-09-30 |
2010-07-13 |
Scynexis, Inc. |
Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
|
CN101309917B
(zh)
|
2005-10-06 |
2013-09-11 |
奥斯拜客斯制药有限公司 |
具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂
|
US20070155820A1
(en)
|
2005-11-23 |
2007-07-05 |
Auspex Pharmaceuticals, Inc. |
Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
|
CN101287742B
(zh)
|
2005-10-12 |
2016-01-06 |
艾德拉药物股份有限公司 |
基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物
|
KR20080075505A
(ko)
|
2005-10-20 |
2008-08-18 |
씨바이오 리미티드 |
과민증의 치료 방법
|
CN101291662A
(zh)
|
2005-10-21 |
2008-10-22 |
诺瓦提斯公司 |
肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
|
EP1945820B1
(en)
|
2005-10-27 |
2013-08-28 |
Janssen Biotech, Inc. |
Toll like receptor 3 modulators, methods and uses
|
WO2007051201A2
(en)
|
2005-10-28 |
2007-05-03 |
Centocor, Inc. |
Tlr3 glycosylation site muteins and methods of use
|
EP1948646A2
(en)
|
2005-11-14 |
2008-07-30 |
Auspex Pharmaceuticals Inc. |
Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
|
CA2631581C
(en)
|
2005-12-01 |
2011-05-03 |
Auspex Pharmaceuticals, Inc. |
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
|
US20070259827A1
(en)
|
2006-01-25 |
2007-11-08 |
University Of Massachusetts |
Compositions and methods for enhancing discriminatory RNA interference
|
WO2007092182A2
(en)
|
2006-01-26 |
2007-08-16 |
University Of Massachusetts |
Rna interference agents for therapeutic use
|
JP5161793B2
(ja)
|
2006-01-27 |
2013-03-13 |
フィブロジェン, インコーポレイテッド |
低酸素症誘導因子(hif)を安定化するシアノイソキノリン化合物
|
CA2641744C
(en)
|
2006-02-10 |
2012-09-25 |
Transtech Pharma, Inc. |
Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
|
EP1986657A4
(en)
|
2006-02-16 |
2011-07-20 |
Discogen Llc |
METHOD OF TREATING A SUBJECT SUFFERING FROM DEGENERATIVE DISCOPATHY BY A MATRIX METALLOPROTEASE INHIBITOR
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
US7674811B2
(en)
|
2006-03-14 |
2010-03-09 |
Ranbaxy Laboratories Limited |
5-lipoxygenase inhibitors
|
US7442706B2
(en)
*
|
2006-03-15 |
2008-10-28 |
Thorner Michael O |
Methods for treating sarcopenia with a growth hormone secretagogue
|
US20070232556A1
(en)
|
2006-03-31 |
2007-10-04 |
Montine Thomas J |
Methods and compositions for the treatment of neurological diseases and disorders
|
CN103497184A
(zh)
|
2006-04-04 |
2014-01-08 |
菲布罗根有限公司 |
作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
|
US20070249519A1
(en)
|
2006-04-20 |
2007-10-25 |
Kalypsys, Inc. |
Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
|
US8536120B2
(en)
|
2006-04-28 |
2013-09-17 |
The Administrators Of The Tulane Educational Fund |
Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
|
CN101516879A
(zh)
|
2006-06-05 |
2009-08-26 |
奥斯拜客斯制药有限公司 |
具有催眠作用的取代的咪唑并吡啶化合物的制备及用途
|
US20070281894A1
(en)
|
2006-06-05 |
2007-12-06 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted erythromycin analogs
|
US20070287734A1
(en)
|
2006-06-09 |
2007-12-13 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
|
AU2007257650A1
(en)
|
2006-06-15 |
2007-12-21 |
Boehringer Ingelheim International Gmbh |
2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
|
KR20090023698A
(ko)
|
2006-06-15 |
2009-03-05 |
베링거 인겔하임 인터내셔날 게엠베하 |
2-아닐리노-4-아미노알킬렌아미노피리미딘
|
AU2007261356A1
(en)
|
2006-06-20 |
2007-12-27 |
Metaproteomics, Llc |
Hexahydro-isoalpha acid based protein kinase modulation cancer treatment
|
US8088733B2
(en)
|
2006-07-06 |
2012-01-03 |
Tranzyme Pharma Inc. |
Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
|
WO2008011621A2
(en)
|
2006-07-21 |
2008-01-24 |
The Penn State Research Foundation |
Protein kinase c zeta inhibition to treat vascular permeability
|
WO2008016677A2
(en)
|
2006-08-02 |
2008-02-07 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of deuterated amphetamines
|
WO2008021891A2
(en)
|
2006-08-08 |
2008-02-21 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
WO2008022285A1
(en)
|
2006-08-16 |
2008-02-21 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of opioid analgesics
|
US20080145313A1
(en)
|
2006-08-30 |
2008-06-19 |
Genesis Research & Development Corporation Limited |
Compositions and Methods for the Treatment and Prevention of Neoplastic Disorders
|
US20090074711A1
(en)
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
US20080221132A1
(en)
|
2006-09-11 |
2008-09-11 |
Xiong Cai |
Multi-Functional Small Molecules as Anti-Proliferative Agents
|
CA2666149A1
(en)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
US9375440B2
(en)
|
2006-11-03 |
2016-06-28 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
WO2008067378A2
(en)
|
2006-11-28 |
2008-06-05 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted phenyltetrazoles
|
US20080146573A1
(en)
|
2006-12-04 |
2008-06-19 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted oxzolidinones
|
US20080167312A1
(en)
|
2006-12-08 |
2008-07-10 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted allylamines
|
EA200901077A1
(ru)
|
2007-02-09 |
2010-04-30 |
Транзим Фарма, Инк. |
Макроциклические модуляторы грелинового рецептора и их применение
|
WO2008103899A1
(en)
|
2007-02-23 |
2008-08-28 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of non-nucleoside reverse transcriptase inhibitors
|
WO2008140859A1
(en)
|
2007-03-15 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
|
AU2008229617A1
(en)
*
|
2007-03-16 |
2008-09-25 |
Novogen Research Pty Ltd |
Method for inducing autophagy
|
BRPI0809171A2
(pt)
|
2007-04-02 |
2014-09-16 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
|
CN101730694A
(zh)
|
2007-04-10 |
2010-06-09 |
奥斯拜客斯制药有限公司 |
用于治疗高血压的取代的氘富集的噻吩
|
WO2008130863A2
(en)
|
2007-04-11 |
2008-10-30 |
Auspex Pharmaceuticals, Inc. |
Substituted benzimidazoles
|
US20080262086A1
(en)
|
2007-04-18 |
2008-10-23 |
Auspex Pharmaceuticals, Inc. |
Substituted anthranilic acids
|
CN101765582A
(zh)
|
2007-04-26 |
2010-06-30 |
奥斯拜客斯制药有限公司 |
氘标记的氯胺酮
|
WO2008141033A1
(en)
|
2007-05-08 |
2008-11-20 |
Auspex Pharmaceuticals Inc. |
Substituted naphthalenes
|
US20080280886A1
(en)
|
2007-05-08 |
2008-11-13 |
Auspex Pharmaceuticals, Inc. |
Substituted ureas
|
WO2008143835A1
(en)
*
|
2007-05-15 |
2008-11-27 |
Yale University |
Ghrelin protects substantia nigra dopamine neurons
|
US20090005309A1
(en)
|
2007-05-18 |
2009-01-01 |
Auspex Pharmaceuticals, Inc. |
Substituted piperidines
|
JP2010527633A
(ja)
|
2007-05-25 |
2010-08-19 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
Toll様受容体3モジュレーター及びその使用
|
WO2008151179A2
(en)
|
2007-06-04 |
2008-12-11 |
Auspex Pharmaceuticals, Inc. |
Substituted phenethylamines
|
JP2010529193A
(ja)
|
2007-06-11 |
2010-08-26 |
ミイカナ セラピューティクス インコーポレイテッド |
置換ピラゾール化合物
|
AU2008266124A1
(en)
|
2007-06-13 |
2008-12-24 |
Auspex Pharmaceuticals, Inc. |
Substituted piperazines
|
TW200909587A
(en)
*
|
2007-06-14 |
2009-03-01 |
Oncotherapy Science Inc |
Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3
|
CA2691379C
(en)
|
2007-06-20 |
2015-06-09 |
Auspex Pharmaceuticals, Inc. |
Substituted n-aryl pyridinones
|
WO2009006413A1
(en)
|
2007-06-30 |
2009-01-08 |
Auspex Pharmaceuticals, Inc. |
Substituted pyrrolidines
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
JP2010537640A
(ja)
|
2007-08-27 |
2010-12-09 |
ボストン バイオメディカル, インコーポレイテッド |
マイクロrna模倣剤または阻害剤としての非対称性rna二重鎖の組成物
|
US7767860B2
(en)
|
2007-09-06 |
2010-08-03 |
Auspex Pharmaceuticals, Inc |
Substituted amino alcohols
|
US20090088401A1
(en)
|
2007-09-27 |
2009-04-02 |
Andres Salazar |
In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic
|